Kalytera Appoints Robert Langer to Scientific Advisory Board
Langer will work with the company to develop its portfolio of cannabidiol candidates for bone health.
Kalytera Therapeutics announced on June 23, 2016 that it has appointed Robert S. Langer to the company’s Scientific advisory board. Kalytera is a California-based pharmaceutical company working to develop a portfolio of non-psychoactive cannabinoid and endocannabinoid medicines.
Langer is a David H. Koch Institute Professor at the Massachusetts Institute of Technology who has received more than 220 awards for his contributions to the drug delivery and tissue engineering fields. Langer will work with Kalytera to advance the company’s portfolio of candidates for bone health.
“Transdermal delivery of cannabidiol, and other proprietary cannabinoids, may confer a variety of benefits to patients,” Langer said in a press announcement. “I look forward to working with Kalytera’s leadership to evaluate and optimally advance the company’s portfolio of drug candidates for bone health.”
Kalytera currently has four drug candidates in its pipeline, including treatments for osteoporosis, bone healing, Prader-Willi Syndrome, and obesity. The company also recently entered into a technology licensing agreement with Delivra Corporation for transdermal technologies for the delivery of cannabidiol, KAL436/439, and KAL671.
Source: Kalytera
EMA Recommends Imfinzi-Based Perioperative Regimen for Treating Resectable NSCLC
March 10th 2025The committee’s recommendation is based on results from a Phase III trial in which Imfinzi demonstrated a reduced risk of recurrence, progression, or death by 32% compared to neoadjuvant chemotherapy alone.
International Women’s Day 2025: A Promising Future for Gender Diversity in Pharma
March 8th 2025In an interview with BioPharm International®, Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
